We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
LGC Clinical Diagnostics

Download Mobile App




AI Tool Uses Imaging Data to Detect Less Frequent GI Diseases

By LabMedica International staff writers
Posted on 05 Nov 2024
Print article
Image: LMU’s Professor Frederick Klauschen developed the novel approach that can improve diagnostic accuracy (Photo courtesy of LMU Munich)
Image: LMU’s Professor Frederick Klauschen developed the novel approach that can improve diagnostic accuracy (Photo courtesy of LMU Munich)

Artificial intelligence (AI) is already being utilized in various medical fields, demonstrating significant potential in aiding doctors in diagnosing diseases through imaging data. However, training AI models requires large datasets, which are typically abundant for common diseases. The real challenge lies in accurately detecting rarer diseases, which many current AI models tend to overlook or misclassify. Researchers have now created a new AI tool designed to utilize imaging data to identify less common gastrointestinal tract diseases effectively.

Developed by scientists at Ludwig Maximilian University of Munich (Munich, Germany) and their collaborators, this innovative model only requires training data from frequently observed conditions to reliably detect rarer diseases. This advancement has the potential to enhance diagnostic accuracy and alleviate the workloads of pathologists in the future. As reported in the New England Journal of Medicine AI (NEJM AI), the new technique is founded on anomaly detection. The model learns to identify and highlight deviations from the precise characterization of normal tissues and findings from common diseases, without the need for specific training on these less frequent cases. The researchers utilized a dataset of 17 million histological images from 5,423 cases for training and evaluation.

In their research, the team gathered two extensive datasets of microscopic images from gastrointestinal biopsy tissue sections, along with their corresponding diagnoses. In these datasets, the ten most common findings—including normal observations and prevalent diseases such as chronic gastritis—constituted approximately 90% of cases, while the remaining 10% encompassed 56 different disease entities, including various cancers. Additionally, the AI model employs heatmaps to visually indicate the location of anomalies within the tissue section. By distinguishing normal findings and common diseases while detecting anomalies, the AI model is poised to offer crucial support to healthcare professionals. Although the identified diseases still require validation by pathologists, this AI tool can significantly reduce diagnostic time, as it enables automatic diagnosis of normal findings and a portion of diseases.

“We compared various technical approaches and our best model detected with a high degree of reliability a broad range of rarer pathologies of the stomach and colon, including rare primary or metastasizing cancers. To our knowledge, no other published AI tool is capable of doing this,” said Professor Frederick Klauschen, Director of the Institute of Pathology at LMU.

Gold Member
Fully Automated Cell Density/Viability Analyzer
BioProfile FAST CDV
Verification Panels for Assay Development & QC
Seroconversion Panels
New
C-Reactive Protein Assay
OneStep C-Reactive Protein (CRP) RapiCard InstaTest
New
Total Thyroxine Assay
Total Thyroxine CLIA Kit

Print article

Channels

Clinical Chemistry

view channel
Image: The tiny clay-based materials can be customized for a range of medical applications (Photo courtesy of Angira Roy and Sam O’Keefe)

‘Brilliantly Luminous’ Nanoscale Chemical Tool to Improve Disease Detection

Thousands of commercially available glowing molecules known as fluorophores are commonly used in medical imaging, disease detection, biomarker tagging, and chemical analysis. They are also integral in... Read more

Immunology

view channel
Image: The cancer stem cell test can accurately choose more effective treatments (Photo courtesy of University of Cincinnati)

Stem Cell Test Predicts Treatment Outcome for Patients with Platinum-Resistant Ovarian Cancer

Epithelial ovarian cancer frequently responds to chemotherapy initially, but eventually, the tumor develops resistance to the therapy, leading to regrowth. This resistance is partially due to the activation... Read more

Microbiology

view channel
Image: The lab-in-tube assay could improve TB diagnoses in rural or resource-limited areas (Photo courtesy of Kenny Lass/Tulane University)

Handheld Device Delivers Low-Cost TB Results in Less Than One Hour

Tuberculosis (TB) remains the deadliest infectious disease globally, affecting an estimated 10 million people annually. In 2021, about 4.2 million TB cases went undiagnosed or unreported, mainly due to... Read more

Technology

view channel
Image: The HIV-1 self-testing chip will be capable of selectively detecting HIV in whole blood samples (Photo courtesy of Shutterstock)

Disposable Microchip Technology Could Selectively Detect HIV in Whole Blood Samples

As of the end of 2023, approximately 40 million people globally were living with HIV, and around 630,000 individuals died from AIDS-related illnesses that same year. Despite a substantial decline in deaths... Read more

Industry

view channel
Image: The collaboration aims to leverage Oxford Nanopore\'s sequencing platform and Cepheid\'s GeneXpert system to advance the field of sequencing for infectious diseases (Photo courtesy of Cepheid)

Cepheid and Oxford Nanopore Technologies Partner on Advancing Automated Sequencing-Based Solutions

Cepheid (Sunnyvale, CA, USA), a leading molecular diagnostics company, and Oxford Nanopore Technologies (Oxford, UK), the company behind a new generation of sequencing-based molecular analysis technologies,... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.